SUMMARY In nine patients with decompensated alcoholic cirrhosis of the liver and impaired renal function the effect of 8-ornithin vasopressin (ornipressin) on renal function and haemodynamic parameters was studied. Ornipressin was infused at a dose of 6 IU/h over a period of four hours. During ornipressin infusion an improvement of renal function was achieved as indicated by an increase of creatinine clearance (76 (15)%; p<OO1), urine volume (108 (29)%; p<O05) and sodium excretion (168 (30)%; p<005). The hyperdynamic circulation of hepatic failure, as characterised by increased cardiac index and heart rate as well as decreased systemic vascular resistance was reversed to a nearly normal circulatory state during ornipressin infusion. The raised noradrenaline plasma concentration (1'74 (031) ng/ml) and plasma renin activity (13-5 (3 9) ng/ml/h) were lowered during ornipressin infusion to 087 (0'21) ng/ml and 5 9 (2-1) ng/ml/h, respectively (p<0-01). The efficacy of a vasoconstrictor agent in reverting a hyperdynamic state and improving renal function provides evidence for the substantial role ofaccumulation of vasodilator substances and subsequent activation of sympathetic nervous system and renin-angiotensin-axis in the pathogenesis of renal dysfunction in hepatic failure. Values are expressed as mean (SE).
Progressive impairment in renal water and sodium excretion frequently develops in patients with advanced hepatic disease and is associated with a poor prognosis. [1] [2] [3] The pathogenetic mechanisms involved in the renal dysfunction are not completely elucidated and consequently, therapeutic approaches are rather limited.
Several pathogenetic mechanisms have been suggested. The absence of morphological abnormalities of the kidney' and the successful transplantation of kidneys from cirrhotic patients dying in oliguric renal failure4 point to a functional impairment rather than tissue damage. Volume as well as non-volume factors have been discussed. A decrease in effective arterial blood volume has been suggested as one of the factors responsible for renal sodium and water retention especially in patients with decompensated cirrhosis and ascites.5 In support of this, renal function improves during plasma expansion, induced either by infusion of plasma expanders6 or by headout water immersion,78 at least in a subgroup of patients. As non-volume dependent factors the increased activity of the sympathetic nervous system"'4 as well as the renin-angiotensin-system,'>'8 impaired renal production of kallikrein and prostaglandins,'"I diminished function of atrial natriuretic peptide2'-13 have been suggested to contribute to the renal dysfunction. None of these proposed mechanisms, however, sufficiently explains the pathogenesis of this complication. Likewise, the therapeutic regimen deduced from these pathogenetic conceptions have been of limited efficacy.
We recently observed 26 Haemodynamic data were recorded two hours, one hour, and just before the infusion of ornipressin, one, two, and four hours after the start of the infusion and one and two hours after the end of infusion.
The thermodilution catheter was also used for collecting mixed venous blood samples for blood gas analysis and oxymetry. Blood samples (arterial and mixed venous) were collected in two hour intervals. Blood gas analysis and oxymetry were done using IL 1303 and IL Co-oxymeter 282 (Instrumentation Laboratory, USA). Oxygen consumption and oxygen transport were calculated with standard formulae.
Urine was collected through a transurethral catheter in two hour periods for measurement of urine osmolality, sodium, and creatinine concentration. Serum osmolality, sodium and creatinine concentrations were measured before starting and at the end of ornipressin infusion. The concentrations of creatinine and sodium were determined by standard photometric methods (ACA DuPont, USA). The osmolality was measured by the freezing point method (Knauer osmometer, FRG). Creatinine clearance, free water clearance and fractionated elimination of sodium were calculated using standard formulas. 27 (5) 80 (5) The improvement of renal function during ornipressin infusion is outlined in Figure 1 and Table 2. In the seven patients with diminished glomerular filtration rate a significant increase of urine volume (from 1-0 (0-3) to 2*6 (1) ml/min), creatinine clearance (from 26 (5) to 43 (8) ml/min 1-73 m2 BSA), urine sodium excretion (from 10-7 (7-0) to 21*6 (14-7) mmolI2 h) and urine sodium concentration (from 22 (8) to 41 (10) mmolIl) in the first two hours of infusion. These values remained raised throughout the infusion period (Fig. 1) . Even in the patient with the lowest creatinine clearance (6.5 ml/min) an improvement to 15 ml/min was achieved during omipressin infusion. After cessation of the infusion the renal parameters returned to preinfusion values. A similar increase in renal function was also achieved in the two patients with a normal creatinine clearance (Table 2) . In all nine patients free water clearance decreased during ornipressin infusion from -16 (9) ml/h to -40 (13) ml/h (p<001). The fractional elimination of sodium increased from 0-66 (0-12) to 1-1 (0-5)% (p<0-01). The observed increase in sodium excretion in response to ornipressin was independent from the initial amount of sodium excreted. A three to four-fold increase in sodium excretion was achieved during ornipressin infusion even in three of the patients in whom sodium excretion was diminished to the low rate of about 10 mmol/24 h (0.4-1-0 mmolI2 h).
The plasma concentration of noradrenaline was initially raised (1-74 (0-31) ng/ml) and decreased to 0-87 (0-21) ng/ml during ornipressin administration.
The plasma renin activity declined from the initially high value of 13*5 (3-9) to 5*9 (2-1) ng/ml/h. The values of noradrenaline and plasma renin activity measured in the presence of ornipressin were, however, still above the normal concentrations (Fig. 2) . No major side effects were observed during ornipressin infusion. All patients responded with an increased bowel activity without abdominal cramps. Facial pallor was evident in two patients. In the electrocardiogram recorded throughout the ornipressin infusion, ST abnormalities were not detected. Omipressin did not affect the pulmonary capillary wedge pressure (Table 1) . Although oxygen transport decreased during ornipressin infusion from 728 (77) to 479 (45) mllmin/m2 as a consequence of the decreased cardiac output, the oxygen consumption did not decrease (124 (8) before and 132 (10) mI/min/ m2 during ornipressin). As plasma lactate concentration did not change (1.7 (0.3) before and 1-5 (0-3) mmolIl during ornipressin) activation of anaerobic metabolism seems unlikely.
Discussion
Progressive renal impairment in advanced hepatic disease is characterised by sodium retention and a decrease in renal blood flow and glomerular filtration rate.'-3 Intimately linked to hepatic failure is also a hyperdynamic circulatory state caused by a profound decrease in peripheral vascular resistance."32 As a baroreceptor mediated response to systemic circulatory alterations the activity of the sympathetic nervous system increases."'-'233 In addition, the renin angiotensin system is activated.'I'8 In the present study we have shown that during infusion of ornipressin in patients with decompensated cirrhosis the above mentioned characteristic changes were attenuated. A considerable improvement in renal function was achieved, as documented by an increase of creatinine clearance, urine volume output, and sodium excretion. The hyperdynamic circulation reverted to a nearly normal haemodynamic state. The increase in the activity of the sympathetic nervous system and renin angiotensin system was I ommmmmma~~~~~~9
suppressed. This uniform effect of ornipressin provides evidence for a closely interrelated pathogenesis of these various organ system dysfunctions in advanced hepatic disease.
Several mechanisms might be involved in the improvement of renal function during ornipressin infusion. Normalisation of mean arterial pressure and/or redistribution of blood flow to the kidneys by ornipressin might result in an increase of renal blood flow by an increase in perfusion pressure and by this enhance renal function. In addition, the decrease in the initially high sympathetic activity during ornipressin infusion induced by the normalisation of blood pressure might have contributed to the efficacy of ornipressin. Increased sympathetic tone is probably involved in natrium and water retention by action at the tubular level3`6as well as by a reduction in renal blood flow caused by renal vasoconstriction.5 101314 The role of the sympathetic nervous system in the pathogenesis of impaired renal function in liver failure is further underlined by the recent observation that lumbal sympathetic blockade by local anaesthesia improved renal function in patients with decompensated cirrhosis.37 Increased sympathetic tone, however, cannot be solely responsible for the decrease in renal blood flow, because blockade of renal alpha-adrenoceptors by phentolamine infusion directly into the renal artery did not alter renal haemodynamics in cirrhotic patients3 and sympathetic block was only effective in cirrhotic patients with basal glomerular filtration rate below 25 ml/ min.37 In this respect it is noteworthy that ornipressin improved renal function even in cirrhotic patients with normal glomerular filtration rate. Furthermore infusion of noradrenaline considerably potentiates the beneficial effect of head-out water immersion on renal function. 38 
